26,545 Shares in Boston Scientific Corporation $BSX Acquired by Integrity Alliance LLC.

Key Points

• Integrity Alliance LLC acquired 26,545 shares of Boston Scientific Corporation, valued at approximately $2.68 million, as part of its recent investment activity.
• Boston Scientific reported earnings of $0.75 per share, exceeding analysts' expectations of $0.72, and generated $5.06 billion in revenue for the quarter, reflecting a 22.8% year-over-year increase.
• Boston Scientific's stock has received several upgraded price targets from analysts, with Barclays raising its target from $125 to $133, indicating strong market confidence.

Integrity Alliance LLC. bought a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 26,545 shares of the medical equipment provider's stock, valued at approximately $2,678,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Investment Management Corp VA ADV purchased a new stake in shares of Boston Scientific during the 4th quarter worth $25,000. Sunbeam Capital Management LLC purchased a new stake in shares of Boston Scientific during the fourth quarter valued at about $26,000. 1248 Management LLC purchased a new stake in shares of Boston Scientific during the first quarter valued at about $26,000. Y.D. More Investments Ltd bought a new stake in shares of Boston Scientific in the 1st quarter valued at about $27,000. Finally, Ameriflex Group Inc. purchased a new position in shares of Boston Scientific in the 4th quarter worth approximately $31,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $105.32 on Thursday. The business's 50 day moving average price is $104.88 and its 200 day moving average price is $102.24. The firm has a market cap of $156.06 billion, a P/E ratio of 62.69, a P/E/G ratio of 2.60 and a beta of 0.65. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm's revenue was up 22.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Barclays raised their target price on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Leerink Partners assumed coverage on Boston Scientific in a research report on Monday, June 16th. They issued an "outperform" rating and a $118.00 price objective for the company. Citigroup reaffirmed a "buy" rating and set a $125.00 target price (up from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Finally, UBS Group boosted their price target on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $117.79.

Insider Activity

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total value of $5,271,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at $18,802,597.06. The trade was a 21.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director owned 18,479 shares of the company's stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $18,397,457 over the last 90 days. Company insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.